T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Recent trials demonstrated that adjuvant trastuzumab emtansine (T-DM1) had some improved outcomes compared to trastuzumab in early analysis. This study reported an updated final analysis of adjuvant T ...

as well as Roche's marketed breast cancer ADC Kadcyla (trastuzumab emtansine). Mirvetuximab soravtansine showed efficacy in a phase 3 trial in ovarian cancer patients last November and is due to ...

It launched Ujvira, (Trastuzumab Emtansine biosimilar) in India, which is the first biosimilar of an Antibody Drug Conjugate (ADC) Kadcyla and a highly effective drug for treatingboth early and ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights increased data management, DE&I, and ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Background and Aims: Neuropathy in association with chronic liver disease, including cirrhosis, is recognized; however, there are differences in the incidence and type of neuropathy reported. The ...

The rising trend in health and lifestyle related problems in the world warrants us to be well informed and health-conscious of the latest happenings in this field. Medindia offers a freely ...

The Amsler grid is a good test for people with Macular Degeneration. The Amsler grid tests the condition of the center of the retina or "macula" ...